Troy Edward Wilson Form 3 Avidity Biosciences / TROY EDWARD WILSON ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

WILSON TROY EDWARD

(Last) (First) (Middle)

C/O AVIDITY BIOSCIENCES, INC.

10975 N. TORREY PINES RD., SUITE 150

(Street)

LA JOLLA CA 92037

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/11/2020

3. Issuer Name and Ticker or Trading Symbol
Avidity Biosciences, Inc. [ RNA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	189,618(1)	D
Common Stock	616,259	I	By family trust
Common Stock	35,553	I	By trust FBO Child 1
Common Stock	35,553	I	By trust FBO Child 2
Common Stock	11,851	I	By trust FBO Child 3
Common Stock	11,851	I	By trust FBO Child 4

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Preferred Stock	(2)	(2)	Common Stock	120,837	0.00	I	By family trust
Series B Preferred Stock	(2)	(2)	Common Stock	16,769	0.00	I	By family trust
Series C Preferred Stock	(2)	(2)	Common Stock	51,436	0.00	I	By family trust

Explanation of Responses:

1. Includes 59,256 shares subject to repurchase by the Issuer, which shares will vest in 15 equal monthly installments beginning on June 29, 2020.

2. The 254,907 shares of Series A Preferred Stock, 35,374 shares of Series B Preferred Stock and 108,504 shares of Series C Preferred Stock are convertible at any time, at the holder's election, at a ratio of one-for-2.1095 shares of the Issuer's common stock, and have no expiration date. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of preferred stock will automatically convert at a ratio of one-for-2.1095 shares of the Issuer's common stock.

Remarks:

	/s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact	06/11/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.